Zealand’s Zegalogue (dasiglucagon) Receives the US FDA’s Approval for the Treatment of Severe Hypoglycemia

March 24, 2021 Auto Bot approval, diabetes, FDA, People, receives, regulatory, Treatment 0

Shots:

  • The approval is based on efficacy results from P-III studies involve assessing Zegalogue vs PBO in children aged 6-17yrs. and in adults with T1D
  • The study met its 1EPs showed an increase in blood glucose of ≥20 mg/dL within 45 minutes, the median time to blood glucose recovery (10min vs 30-45min), following injection of 0.6 mg/0.6 ml of therapy, 99% of patients recovered within 15 minutes in adults
  • Zegalogue will be available in both an auto-injector and a prefilled syringe to treat hypoglycemia in patients with diabetes aged ≥6yrs.

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Zealand Pharma

The post Zealand’s Zegalogue (dasiglucagon) Receives the US FDA’s Approval for the Treatment of Severe Hypoglycemia first appeared on PharmaShots.